Blog Viewer

Volume LVII, Number 1

Anita Trupiano
Rutgers Cancer Institute

Rani Muthukrishnan
Texas A&M University- San Antonio

Abstract

Research Administrators play a pivotal role in ensuring the success and compliance of clinical research projects registered in ClinicalTrials.gov. However, in practice, this process requires successful contributions from various stakeholders. Based on insights from research administrators, this study presents the challenges, best practices, and proposed solutions to streamline these processes. Through interviews with professionals across institutions, this article delves into the practical strategies to optimize the processes required by Research Administrators for maintaining a robust ClinicalTrials.gov presence.

Keywords: rClinicaltrials.gov; FDAAA 801 Compliance; FDA; Research Administrators; Best Practices; Institutional Oversight

Introduction

ClinicalTrials.gov is a public registry managed by the U.S. National Library of Medicine at the NIH, holding over 444,000 trials from 221 countries. It was established by the Food and Drug Administration Modernization Act of 1997 and expanded by the Food and Drug Administration Amendments Act of 2007 (FDAAA, Sidebar 1) to include results reporting. This database allows researchers, patients, and the public to access information about clinical trials, including their purpose, eligibility, locations, and outcomes. Thus, ClinicalTrials.gov is essentially a powerful platform for ensuring transparency and accountability in clinical research.

Sidebar 1:

FDAAA 801 Regulatory Background: FDAAA 801 and Its Impact on Compliance
The Food and Drug Administration Amendments Act of 2007 (FDAAA 801) is a landmark regulation that mandates the registration and results reporting of certain clinical trials on ClinicalTrials.gov. It applies to Applicable Clinical Trials (ACTs), including most interventional studies of FDA-regulated drugs, biological products, and devices.

FDAAA 801 requires that:

• Trial registration must occur no later than 21 days after enrollment of the first participant.
• Results reporting must be submitted within 12 months of the primary completion date, regardless of whether the trial was completed or terminated early.
• Specific information such as study design, outcome measures, and adverse event data must be accurately reported.

The law includes enforcement mechanisms, such as civil monetary penalties, public notices of noncompliance, and potential loss of NIH funding, making compliance critical for institutions and investigators. FIDDA trial tracker is now available for all institutions (https://fdaaa.trialstracker.net/). Institutions must develop processes—often involving both IRB offices and ClinicalTrials.gov administrators—to determine whether a trial meets the ACT definition. IRBs, while not responsible for registering studies, often assist in identifying applicable studies and advising on consent language that meets FDAAA 801 and NIH policy requirements.

By integrating IRB protocols with ClinicalTrials.gov workflows, institutions can help mitigate the risk of noncompliance and support transparency in research, which ultimately protects human subjects and strengthens public trust in science.

Research suggests ClinicalTrials.gov is crucial for transparency, scientific advancement, patient recruitment, regulatory compliance, informed consent and public trust. Registering a study in ClinicalTrials.gov provides transparency as the trial information is publicly available, thereby building trust and allowing oversight of research ethics. Researchers can avoid duplication by finding results of the trials, and patients who are seeking treatments for their conditions may be able to access experimental treatments.

The success of a clinical trial depends not only on scientific rigor but also on regulatory compliance. Because of the emphasis to promote openness, ClinicalTrials.gov requires the registration and results reporting of certain clinical trials, particularly those involving investigational drugs or devices, under federal regulations such as FDAAA. Compliance with these requirements is non-negotiable, as failure can lead to significant consequences, including funding delays, legal penalties, and reputational damage. Behind this complex process, research administrators play an indispensable role, ensuring that clinical trials meet these standards. This article explores their critical responsibilities, supported by insights from authoritative sources and real-world practices, highlighting their impact on maintaining ClinicalTrials.gov compliance.

Understanding ClinicalTrials.gov and Its Compliance Framework

ClinicalTrials.gov serves as a global registry, providing detailed information about clinical studies conducted worldwide. It was created to enhance transparency, ensuring that patients, healthcare providers, and the public have access to accurate and timely data about ongoing and completed trials. Governed by federal laws, including FDAAA and 42 CFR Part 11, the platform mandates specific compliance requirements:

• Registration: Applicable clinical trials must be registered within 21 days of enrolling the first participant, as outlined by the NIH at https://grants.nih.gov/policy-and-compliance/policy-topics/clinical-trials/reporting/steps.
• Updates: Study records must be updated at least annually to reflect changes in protocol, recruitment status, or other details.
• Results Reporting: Results must be submitted within one year of the primary completion date, with provisions for extensions under certain conditions.
• Accuracy and Completeness: All submitted information must adhere to the required data elements, ensuring clarity and compliance with federal regulations.

These requirements are designed to foster trust and accountability, but their complexity can be daunting for research teams. This is where research administrators step in, acting as the administrative backbone of clinical research compliance.

Compliance with ClinicalTrials.gov reporting requirements has been a persistent challenge for many institutions. A 2015 study published in the New England Journal of Medicine analyzed 13,327 applicable clinical trials and found that only 13.4% reported summary results within the mandated 12-month period after trial completion, and 38.3% reported results at any time up to September 2013 (Anderson et. al., 2015). This indicates that a significant majority of institutions were non-compliant during that period.

More recent data suggests some improvement. A 2020 study revealed that 41% of completed clinical trials reported results within the 1-year legal deadline, while 36% had not reported by September 2019 (DeVito et al., 2020). Despite this progress, a substantial proportion of institutions remained non-compliant. These findings underscore the ongoing need for enhanced compliance strategies and institutional commitment to meet federal reporting obligations.

As of March 2025, comprehensive data on ClinicalTrials.gov compliance rates for this year are not yet available. However, recent studies indicate ongoing challenges in achieving full compliance with clinical trial reporting requirements. For instance, a January 2025 analysis revealed that twelve-month reporting rates increased from 8.3% to 23.2%, while thirty-six-month rates rose from 40.8% to 49.2%. These findings suggest that while improvements have been made, a significant proportion of institutions continue to face difficulties in meeting reporting obligations (Mughal et al., 2025).

It's important to note that compliance rates can vary significantly across different institutions and funding sources. For example, a 2015 study found that industry-funded trials had higher compliance rates compared to those funded by the National Institutes of Health (NIH) or other government or academic institutions (Laterre & François, 2015). This variability underscores the need for ongoing efforts to enhance compliance strategies and ensure timely reporting of clinical trial results.

The Multifaceted Role of Research Administrators in Compliance

Research administrators are critical members of the research workforce, responsible for the administrative, financial, and regulatory oversight of sponsored research projects, including clinical trials. Their role in ensuring ClinicalTrials.gov compliance is multifaceted and essential, bridging the gap between scientific teams and regulatory bodies. Below are their key responsibilities, drawn from various institutional guidelines and reports:

1. Registration and Maintenance of Study Records:
   Research administrators are tasked with ensuring that clinical trials are registered on ClinicalTrials.gov within the mandated 21-day window. This involves coordinating with principal investigators (PIs) to gather necessary information, such as study protocols, eligibility criteria, and funding details. For instance, at Washington University, clinical research coordinators (CRCs), a subset of research administrators, are explicitly responsible for assisting PIs in registering studies and maintaining current information on the site, as detailed at https://research.wustl.edu/about/roles-responsibilities/clinical-research-coordinator/. They also ensure that study records are updated annually, reflecting any changes in protocol, recruitment status, or results, which are critical for compliance and transparency. University of Rochester also provides a similar service, University of Rochester Clinical Trials Registration: https://www.urmc.rochester.edu/clinical-translational-science-institute/services-and-support/clinical-trials-registration.
2. Compliance with Regulatory Requirements:
   Research administrators must ensure that all clinical trials meet the regulatory standards set by the FDA, NIH, and other funding agencies. This includes understanding the specific requirements for ClinicalTrials.gov registration and results reporting, as well as ensuring that the study team complies with these mandates. They navigate the complex landscape of clinical research regulations, which involve multiple oversight bodies, such as the Office for Human Research Protections (OHRP) and institutional review boards (IRBs). For example, at Case Western Reserve University, research administrators are highlighted as key players in reducing regulatory burden by providing investigators with awareness of requirements and acceptable standards for clinical trials, as noted at https://case.edu/medicine/ctsc/clinical-study-resources/regulatory-compliance.
3. Education and Guidance:
   A significant, often underappreciated, role of research administrators is as educators. They provide guidance to PIs and study teams on the importance of ClinicalTrials.gov compliance, ensuring that all team members understand their roles in maintaining accurate and timely reporting. The Clinical Trials Transformation Initiative (CTTI) emphasizes that research administrators should keep PIs and study teams informed and provide education on how to meet requirements, as discussed at https://ctti-clinicaltrials.org/our-work/quality/challenges-meeting-u-s-clinicaltrials-gov-reporting-requirements/. This educational role is crucial for fostering a culture of compliance and reducing the risk of errors, such as missed deadlines or incomplete submissions.
4. Proactive Compliance Management:
   Research administrators are proactive in identifying potential compliance issues before they escalate. They monitor study progress, track deadlines for registration and reporting, and ensure that all necessary documentation is in place. This proactive approach helps mitigate risks, such as funding delays or legal penalties, which can arise from non-compliance. For instance, the CTTI report recommends that research administrators take proactive steps to comply with ClinicalTrials.gov requirements, highlighting their role in ensuring timely and accurate reporting. 
   
   At Washington University, clinical research coordinators are tasked with assisting PIs in registering studies on ClinicalTrials.gov and maintaining current information, a responsibility critical for ensuring institutional compliance with federal regulations. This framework, detailed at https://research.wustl.edu/about/roles-responsibilities/clinical-research-coordinator/, highlights their direct involvement in compliance processes.
5. Collaboration with Stakeholders:
   Research administrators act as liaisons, facilitating communication between PIs, IRBs, regulatory affairs teams, and funding agencies. They ensure that all parties are aligned on compliance goals, coordinating efforts to meet deadlines and address regulatory queries. At Northwestern University, research administrators assist PIs in ensuring that research records, including IRB submissions and regulatory records, are updated contemporaneously, which is vital for maintaining accurate ClinicalTrials.gov records, as outlined at https://researchroles.northwestern.edu/admin-research-personnel/.

Training for Research Administrators is relatively sparse, however the success of The Integrated Translational Health Research Institute of Virginia (iTHRIV)’s training in this area is notable. iTHRIV developed the Research Administration Program for Training and Resources (RAPTR) to address the growing complexity of clinical and translational research. This program, supported by NIH-NCATS, includes training on post-award administration, which encompasses compliance with reporting requirements such as those for ClinicalTrials.gov. The program’s success, with components like online training and mentoring, underscores the need for well-trained research administrators to manage regulatory demands, as detailed in the study at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627806/.

In this article we showcase the real-life scenarios and profiles of two Research Administrators from two research intensive institutions designated as R1 to answer the question: How can Research Administrators optimize the ClinicalTrials.gov process for assuring compliance at all stages of the trial?

Methods

Since we conducted the interview via email, we provided objectives of each question to ensure the context is clear to the participants.

The chief objective of our arc of questions was to obtain information from the Research Administrators regarding all the steps involved in the process end to end, explore participants’ views, data entry and other administrative tasks, capacity building, identify recurring issues and compliance, and closeout studies (see Appendix). With the answers, we present a view of the entire process, the responsibilities, and the perspectives of the stakeholders to be managed in this complex process.

This study employed a qualitative approach to explore institutional strategies, compliance challenges, and best practices related to ClinicalTrials.gov registration and reporting processes. The research was conducted in two phases: semi-structured interviews and thematic analysis.

Participants

Key personnel involved in ClinicalTrials.gov compliance from two major research institutions were invited to participate. Weill Cornell Medicine (WCM) and University of Rochester Medical Center (URMC) provided detailed input for this article (Sidebar 2).

Sidebar 2

Profile of the respondents: Dr. Carrie Dykes and Lauren Odynocki
Dr. Carrie Dykes is the Director of Research Services at the University of Rochester Medical Center (URMC). In this role, she oversees a broad range of regulatory, compliance, and administrative functions to support principal investigators and research teams. Her work focuses on streamlining ClinicalTrials.gov compliance, supporting study teams with results reporting, and ensuring alignment between regulatory requirements and institutional policies.

Dr. Dykes leads a PI-led model at URMC, where investigators maintain primary responsibility for ClinicalTrials.gov registration and reporting, supported by centralized administrative resources. She has implemented targeted training programs and real-time administrative support to enhance research compliance and efficiency. Her experience provides valuable insight into balancing regulatory obligations with investigator autonomy in a complex academic research environment. Dr. Dykes contributed to this study by sharing detailed institutional practices and offering strategic insights into improving compliance processes and IRB alignment.

Lauren Odynocki, Senior Human Research Compliance Specialist at Weill Cornell Medicine (WCM) in New York City has extensive experience in regulatory compliance and plays a key role in overseeing ClinicalTrials.gov registrations, updates, and results reporting for the institution. Lauren manages a robust compliance infrastructure that includes institutional policies, quality control (QC) reviews, and coordination with the IRB and Clinical Trial Management System (CTMS). Her tailored training sessions for study teams provide detailed guidance on navigating regulatory requirements and prevent noncompliance with federal deadlines.

Lauren’s comprehensive approach emphasizes education, accuracy, and collaboration. Her work ensures that investigators are well-supported and that institutional records remain consistent across multiple regulatory systems. In this study, Lauren provided in-depth insights into WCM’s structured processes and the role of institutional oversight in ensuring research transparency and accountability.

Data Collection

Participants were contacted via email and invited to complete a series of open-ended questions (see Appendix) related to their institutional workflows, challenges, and strategies. Respondents had the option to participate through written responses and followed up with phone calls for clarification.

Ethical Considerations

All participants were informed that the data collected would be used for publication purposes and could choose whether to have their name and institution identified in the final manuscript. Since these were case studies, no approval from the Institutional Review Board was required.

Data Analysis

Responses were transcribed and analyzed using a thematic analysis framework. Recurring patterns and insights were coded into key categories: institutional structure, compliance enforcement, training and education, integration with IRB, and proactive strategies. Common challenges and innovative solutions were identified and synthesized into institutional profiles for comparative analysis.

Results & Analysis

The results of our interviews and analysis showed the management of studies posted on ClinicalTrials.gov is resource intensive and requires high-level micromanaging.

Institutional Structure

Establishing a robust institutional structure to be efficient and effective in supporting, monitoring, and providing guidance requires accountability, process, procedures, standard guidelines and enforcement capabilities to be a part of the system which allows for constant feedback mechanisms at all levels. The institutional strategies are listed in Table 1.

Table 1. Institutional Strategies

The ClinicalTrials.gov program at WCM is overseen by the Chief Research Compliance Officer through the Office of Research Integrity, which houses Human Research Protections—an office that includes the ClinicalTrials.gov program and the IRB. Human Research Protections collaborates internally and with WCM’s Joint Clinical Trials Office to provide robust ClinicalTrials.gov support to investigators entering information into ClinicalTrials.gov.

At URMC, although the Principal Investigator is responsible for the entire process, the oversight begins at the senior levels with the Senior Associate Dean establishing a process improvement committee for research with representation from all research offices including the IRB, project administration, Office of Counsel, privacy, etc. The Office of Regulatory Support within the UR Clinical and Translational Science Institute (UR CTSI) supports PIs in the complex ClinicalTrials.gov process by providing education and training to register studies and report results.

Administrative controls enable optimal reporting on ClinicalTrials.gov. At WCM, for example, the institution is designated in PRS as the Responsible Party. Lauren notes, “...we’re able to conduct internal QC reviews of any information plugged into ClinicalTrials.gov [for registrations and updates]. This allows us to leverage the CTMS and IRB systems and reference the protocol document in our work with the study team to ensure data integrity.”

Training and Education

Although the researcher is responsible for reporting the study, and the PI is named the responsible party on ClinicalTrials.gov forum, PIs may delegate this responsibility to other members of their team. “We educate them on how to register studies and report results. We create registrations or enter results for them. We remind them when records need updating. We also email them regularly once the study completion date has been determined and until results are entered,” said Carie.

At WCM, training is tailored and held on demand, along with a quarterly ClinicalTrials.gov training serving both the specialized and generic requirements of the audience. Lauren noted, “We track training effectiveness with post-training surveys.”

Integration with IRB

At URMC, the Office of Regulatory Support and the IRB office keep each other informed about policies related to ClinicalTrials.gov and ethics and work together with study teams to create a record that satisfies all policies. The NCT# is a required part of the IRB application for studies that require registration by FDAAA or the NIH.

At WCM, the ClinicalTrials.gov Program also checks IRB agendas to capture studies that require registration. “IRB Analysts also notify researchers of which clinical trial definition applies, if any, so they can be sure to include the appropriate ClinicalTrials.gov statement in the informed consent form, and register their study if needed. We will email the PI to inform them, if registration hasn’t already been completed,” said Lauren.

Proactive Strategies

At UMRC, having noted that the outcome measures are the hardest for the PIs, the Office of Regulatory Support, “... encourages PIs to work with the PRS administrators in our office to complete records, offer to review records before they are submitted for review and use checklists to ensure consistency.”

Another strategy is having dedicated officers with committee guidance to improve compliance by having a dedicated person study teams can go to for help. The officer must be knowledgeable about different types of trial designs, clinical research in general, and have experience with the CT.gov system and its requirements for how data is entered.

Monthly review of ClinicalTrials.gov portal ensuring prompt, frequent, and timely updates as required has also been fruitful. Carie and Lauren agree that the lack of responses from PIs or team members when records need to be changed is a huge obstacle for timely reporting. Other significant obstacles include lack of clear outcome measures in protocols; a system to track records proactively instead of reactively; and the inability to convince institutional leadership of the importance of transparency and regulatory compliance so that adequate resources are provided to PIs and Administrators.

For many researchers, the outcome measures are the hardest to complete. Carie notes, “We encourage PIs to work with the PRS administrators in our office to complete records, offer to review records before they are submitted for review and use checklists to ensure consistency. We send monthly reminders once a study enters the 12-month results entry window. This provides them a countdown after the study completion date. However, it still takes teams longer than 12 months to get the results analyzed mostly due to competing priorities and lack of resources.”

Compliance Enforcement

Compliance requires both training and support. At WCM, both education and training are provided to ensure compliance. Lauren noted, “The support we provide to researchers for results reporting hinges on their timely updates to the primary and study completion dates, so in training we place a big emphasis on understanding these regulatory terms.”

A common strategy to ensure compliance is to enforce an institutional deadline. At WCM, the internal due date for results ensures the results are submitted in advance of the federal deadline. Noncompliance with that internal due date triggers an escalation policy that has allowed the research administrators to work with study teams to resolve any results entry problems prior to the federal results deadline. Perhaps, it also means the study teams have less time to wrap up their data analysis. However, as Lauren noted, “Operating this way acts as insurance against any noncompliance with federal requirements and it protects the researcher in the end.” Delays in reporting results can result in withdrawal of funding.

Discussion & Conclusion

The complexity of clinical research compliance cannot be overstated. Research administrators are often the unsung heroes who ensure that the administrative and regulatory aspects of clinical trials run smoothly. Their expertise in navigating regulatory requirements, managing deadlines, and coordinating with multiple stakeholders is essential for maintaining ClinicalTrials.gov compliance. Without their oversight, clinical trials risk delays, funding issues, and even legal repercussions, which can undermine the integrity of the research process.

Both URMC and WCM emphasize balancing PI autonomy with strong administrative support. WCM's structured tracking and escalation policies serve as a proactive compliance mechanism, while URMC’s hands-on approach fosters direct collaboration between administrators and researchers. Both institutions highlight the importance of educational outreach in ensuring researchers fully grasp compliance requirements.

Key Takeaways and Recommendations

Based on the insights gathered, this study highlights three essential strategies for institutions aiming to optimize ClinicalTrials.gov compliance:

1. Invest in Dedicated Administrative Capacity and Training: The success of both URMC and WCM underscores the importance of having trained, proactive research administrators. Institutions should prioritize the development of specialized training programs and provide sufficient administrative staffing to meet compliance demands effectively.
2. Integrate Compliance Workflows Across Departments: Compliance is most successful when ClinicalTrials.gov activities are well-integrated with IRB processes, CTMS systems, and study teams. Cross-departmental collaboration streamlines workflows, minimizes errors, and supports a culture of shared accountability.
3. Adopt Proactive Compliance Monitoring and Escalation Policies: Institutions benefit from implementing internal deadlines, regular quality control checks, and clear escalation procedures. These practices help research teams identify and resolve compliance challenges early, reducing the risk of missed federal deadlines and associated penalties.

By embracing these practices, institutions can strengthen their ClinicalTrials.gov processes, promote research transparency, and safeguard public trust in the research enterprise.

Research administrators contribute to the broader goal of advancing medical research by ensuring that clinical trials are conducted ethically and transparently. Their role in maintaining accurate and up-to-date information on ClinicalTrials.gov supports public trust, facilitating access to critical information for patients and healthcare providers. This educational impact, often underappreciated, is a vital component of their contribution, fostering a culture of compliance and accountability.

Limitations

The study focused on a small number of institutions with strong compliance infrastructures, which may not represent the broader spectrum of institutions with more limited resources. Future research may expand to include a more diverse range of sites.

Conclusion

The role of research administrators in ClinicalTrials.gov compliance is both critical and multifaceted. Their contributions go beyond regulatory tasks; they serve as the foundation for ensuring transparency, accuracy, and accountability in clinical research. The experiences of URMC and WCM highlight that successful compliance is not achieved by chance but through dedicated administrative capacity, targeted training, and institutional commitment.

To strengthen compliance practices, institutions should prioritize three key strategies: investing in research administrator training and staffing, fostering cross-departmental collaboration among IRBs, compliance offices, and research teams, and implementing proactive quality control and escalation procedures. These measures can significantly reduce the burden on principal investigators while improving the accuracy and timeliness of reporting.

Ultimately, optimizing ClinicalTrials.gov processes is not just a regulatory requirement, it is a commitment to research integrity and public trust. By recognizing and supporting the vital role of research administrators, institutions can elevate the quality and reliability of their clinical research programs.

Author Note

The authors have no known conflict of interest to disclose.

Anita Trupiano
Rutgers Cancer Institute

Rani Muthukrishnan
Texas A&M University- San Antonio
https://orcid.org/ 0000-0001-9681-5172

Correspondence concerning this article should be addressed to Dr. Rani Muthukrishnan, Executive Director of Research Compliance, Texas A&M University- San Antonio, Texas 78224. Email: rmuthukrish@tamusa.edu

Acknowledgements: The authors acknowledge the support of their colleagues in SRAI, Dr. Carrie Dykes and Lauren Odynocki for their prompt responses. Dr. Dykes’s project described in this publication was supported by the University of Rochester CTSA award number UL1 TR002001 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

Anderson, M. L., Chiswell, K., Peterson, E. D., Tasneem, A., Topping, J., & Califf, R. M. (2015). Compliance with results reporting at ClinicalTrials.gov. The New England Journal of Medicine, 372(11), 1031–1039. https://doi.org/10.1056/NEJMsa1409364

Case Western Reserve University School of Medicine. (n.d.). Regulatory and compliance resources. Clinical and Translational Science Collaborative. Retrieved March 29, 2025, from https://case.edu/medicine/ctsc/clinical-study-resources/regulatory-compliance

Clinical Trials Transformation Initiative. (n.d.). Challenges meeting U.S. ClinicalTrials.gov reporting requirements. Retrieved March 29, 2025, from https://ctti-clinicaltrials.org/our-work/quality/challenges-meeting-u-s-clinicaltrials-gov-reporting-requirements/

Clinical Trials Transformation Initiative. (2024). Improving timely, accurate, and complete registration and reporting of summary results information on ClinicalTrials.gov. https://ctti-clinicaltrials.org/wp-content/uploads/2024/01/CTTI_SuggestedPractices_ClinicalTrials-gov_FINAL.pdf

DeVito, N. J., Bacon, S., & Goldacre, B. (2020). Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: A cohort study. The Lancet, 395(10221) 361-369. https://doi.org/10.1016/s0140-6736(19)33220-9

Laterre, P. F., & François, B. (2015). Strengths and limitations of industry vs. academic randomized controlled trials. Clinical Microbiology and Infection, 21(10), 906-909. https://www.sciencedirect.com/science/article/pii/S1198743X1500720X

Mughal, Z., Fu, R., Luechtefeld, T., Chiswell, K., Kleinstreuer, N., Shaw, G., & Tidmarsh, G. F. (2025). Compliance with results reporting at ClinicalTrials.gov before and after the 2017 FDAAA Final Rule: A comparative analysis. Journal of Applied Public Health, 3(1). https://doi.org/10.70542/rcj-japh-art-vr3aga

National Institutes of Health. (n.d.). Steps to compliance for NIH awardees on clinical trials reporting. Retrieved March 29, 2025, from https://grants.nih.gov/policy-and-compliance/policy-topics/clinical-trials/reporting/steps

University of Virginia School of Medicine Office for Research. (n.d.). Roles and responsibilities in research administration: The award process at UVA. Retrieved March 29, 2025, from https://med.virginia.edu/office-for-research/resources/roles-and-responsibilities-in-research-administration/

Washington University in St. Louis Office of the Vice Chancellor for Research. (n.d.). Clinical research coordinator roles and responsibilities. Retrieved March 29, 2025, from https://research.wustl.edu/about/roles-responsibilities/clinical-research-coordinator/

Appendix

Interview Questions

1) How does your institution handle ClinicalTrials.gov registrations, updates, and results reporting? How does your institution support researchers in meeting results, reporting deadlines and requirements?

Objective: To understand institutional practices.

2) What is the typical workflow for a study requiring ClinicalTrials.gov registration at your institution?

Objective: To explore typical workflows of ClinicalTrials.gov.

3) In your opinion, how does the process of registering studies on ClinicalTrials.gov enhance transparency and regulatory compliance in research?

Objective: Explore participants’ views on the benefits and significance of ClinicalTrials.gov.

4) What institutional or administrative challenges have you encountered while managing a ClinicalTrials.gov account or fulfilling the responsibilities associated with being a Principal Investigator?

Objective: Uncover barriers to effective account management and role differentiation.

5) How do you determine whether a study meets the criteria for mandatory ClinicalTrials.gov registration, particularly when balancing sponsor-investigator roles? What steps do you take to ensure timely registration before participant enrollment?

Objective: Uncover strategies for identifying eligible studies and adhering to registration timelines.

6) From your experience, what are the most challenging aspects of accurately completing the mandatory information fields for ClinicalTrials.gov (e.g., study title, design, outcomes)? How do you ensure clarity and compliance in the information provided?

Objective: Gain insights into best practices for addressing the complexities of required data Entry.

7) Can you share how you or your team manage updates to study information, such as protocol changes or recruitment status updates, to maintain compliance with ClinicalTrials.gov requirements?

Objective: Highlight practical approaches to ongoing maintenance of registration

8) What challenges have you encountered when adhering to results reporting deadlines, and what strategies do you recommend for ensuring accurate and timely submissions?

Objective: Explore solutions for navigating the results reporting process and meeting regulatory deadlines effectively.

9) What steps or resources have you found most helpful when aligning the requirements of IRB approval and ClinicalTrials.gov registration for your studies? What steps does your institution take to ensure compliance with ClinicalTrials.gov requirements?

Objective: Identify practical solutions and resources used by researchers to meet overlapping requirements.

10) Based on your experience, what best practices or strategies would you recommend to ensure compliance with both IRB protocols and ClinicalTrials.gov requirements?

Objective: Gather actionable insights and suggestions for improving compliance practices.

11) Describe your approach ensuring compliance with regulatory standards, such as FDAAA 801 and NIH policies, while also aligning with global ethical guidelines during the IRB application process.

Objective: Gather insights into strategies for managing multiple regulatory and ethical Frameworks.

12) Based on your experience, what are the most common challenges researchers face with ClinicalTrials.gov registration and updates, such as delays, inaccuracies, or missing result submissions? How can these issues be effectively addressed? What are the most common challenges or delays you encounter during the ClinicalTrials.gov registration or results reporting process? With examples.

Objective: Identify recurring problems and practical solutions for improving compliance.

13) Can you share any insights or lessons learned from case studies or examples where studies faced legal penalties, funding withdrawal, or reputational damage due to non-compliance with ClinicalTrials.gov requirements? What are the biggest obstacles researchers face in reporting results to ClinicalTrials.gov?

Objective: Highlight real-world consequences and actionable takeaways for avoiding compliance failures.

14) What role do education and training, such as workshops or seminars, play in improving researchers and staff’s understanding of ClinicalTrials.gov and IRB requirements? Can you share examples of effective training programs? What training or support is provided to researchers and study teams at your institution regarding ClinicalTrials.gov? Can you share an example of a successful training session or resource that significantly improved compliance at your institution?

Objective: Gain insights into best practices for education and capacity building.

15) How does institutional oversight, such as having dedicated compliance officers or committees, help mitigate compliance risks. What challenges have you encountered in implementing or maintaining such structures? What tools or systems does your institution use to manage ClinicalTrials.gov compliance? Tableau, Excel spreadsheet? What additional technological resources do you think would help improve compliance or reduce delays?

Objective: Explore the impact and hurdles of institutional mechanisms for compliance monitoring.